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The Policy Research Unit in Economic Evaluation of Health and Care interventions is funded by the 
Department of Health Policy Research Programme. It is a collaboration between researchers from 
the University of Sheffield and the University of York.  
 
 
The Department of Health's Policy Research Unit in Economic Evaluation of Health and Care 
Interventions is a 7 year programme of work that started in January 2011.  The unit is led by 
Professor John Brazier (Director, University of Sheffield) and Professor Mark Sculpher (Deputy 
Director, University of York) with the aim of assisting policy makers in the Department of Health to 
improve the allocation of resources in health and social care. 
 
This is an independent report commissioned and funded by the Policy Research Programme in the 
Department of Health. The views expressed are not necessarily those of the Department. 
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Acronym Definition 
AMSTAR Assessing the quality of systematic reviews 
ADCS-ADL Alzheimer Disease Cooperative Study-Activities of daily living scale 
ADRQL ůǌŚĞŝŵĞƌ ?ƐŝƐĞĂƐĞ-Related QOL 
BSC Best supportive care 
CDR Clinical Dementia Rating 
DQoL Dementia Quality of Life instrument 
EMA European Medicines Agency 
EQ-5D EuroQol 5 dimensions 
FR Future research 
HRQoL Health related quality of life   
HS Health states 
HTA(s) Health technology assessment(s) 
HUI Health Utility Index 
KGV Known group validity 
MMSE Mini-mental State Examination 
MTA Multiple technology assessment 
NAD National Audit of Dementia 
NCA National Clinical Audit 
NHS National Health Service 
PR Potential recommendations 
PROM(s) patient reported outcome measure(s) 
QALY(s) Quality adjusted life year(s) 
QOL-AD Quality of Life  W ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ 
QWB Quality of Well Being 
R&D Research and development 
RCT(s) Randomised controlled trial(s) 
TA(s) Technology Appraisal(s) 
TAG Technology Assessment group 
UK United Kingdom 
WP Work package 
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1. BACKGROUND 
EEPRU was approached by Jason Cox (Research and development (R&D) Division) to prepare a 
programme of research to support the appropriateness of, and use of, patient reported outcome 
measures (PROMs) collected for the National Clinical Audit (NCA).  The EEPRU programme was 
informed by a R&D template prepared by Simon Bennett, Steve Fairman and Keith Willett at 
National Health Service (NHS) England. 
 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the NHS, 2) compare the cost-effectiveness 
of alternative providers in delivering the specific services (i.e. linking outcomes and resource use), 
and 3) assess the cost-effectiveness of alternative interventions and other changes in the NHS.  The 
intention is to introduce PROMs across a range of conditions over the next 3 years commencing with 
13 conditions in the 2014/15 NCA programme.  
 
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the Department of Health (DH) (8
th
 November 2013).  The current document 
provides details on the objectives, methodology and results for Work Package 1 (WP1): to determine 
what PROMS should be used in the 13 health conditions specified in the 2014/15 NCA programme. 
 
2. OVERVIEW 
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the EuroQol 5 dimensions (EQ-5D) is appropriate in the 13 health 
conditions specified in the 2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
 
Each component consists of a series of reviews of the literature. 
 
This Appendix provides the detailed results for the condition dementia and should be read in 
conjunction with both the main report and the methods/search strategy appendices. 
EEPRU NCA Appendix J: Dementia 
Page 6 
 
3. METHOD 
The full detailed methodology used is provided in Appendix A, including the search strategy, 
selection criteria for studies included, and data extraction etc.  In summary, a review of the literature 
was undertaken to assess the appropriateness of the EQ-5D in terms of classic psychometric criteria 
(WP1.1); where the EQ-5D was not considered appropriate, additional searches were undertaken to 
identify alternative measures (WP1.2); and finally, existing health technology appraisals were 
reviewed and data requirements were compared with variables currently collected in the dementia 
audit (WP1.3).   
 
3.1 Psychometric properties (WP1.1) 
Assessments reported in the included studies were categorised according to the following 
definitions: 
 
Acceptability 
Data relating to how acceptable the measure was to the person completing it, expressed as the 
proportion of completed surveys, or the proportion of missing data. 
 
Reliability 
There are two main definitions for reliability, a) the degree to which a measure reproduces the same 
results in an unchanged population and b) the degree to which a measure reproduces the same 
results when completed by different assessors (e.g. patient and proxy report). In both cases, 
reliability can be assessed by re-testing, and calculating the correlations or difference between tests. 
In case a) the comparison may be between the same populations separated by time, where no 
change in health state was observed (as compared to using an alternative condition specific or 
generic measure). In case b) the measure may be completed by multiple people (proxies) on the 
ƉĂƚŝĞŶƚ ?Ɛ ďĞŚĂůĨ ĂŶĚ ƚŚĞŝƌ ƌĞƐƉŽŶƐĞƐ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƚŚŽƐĞ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ? tŚĞƌĞ ƚŚĞ ŽƵƚĐŽŵĞ
measure is specifically designed for self-report by patients, this test of reliability may be expected to 
produce less agreement.  
 
Construct validity 
This is an assessment of how well an instrument measures what it intends to measure. Two main 
definitions are used in this review.  
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a) Known group validity, where estimates for groups that are known to differ in a concept of interest 
are compared either qualitatively or statistically. The known groups may be defined using other 
measures, according to clinical categorisation.  
b) Convergent validity assesses the extent to which a measure correlates with other measures of the 
same or similar concepts. Correlation coefficients were considered low if <0.3, moderate if between 
0.3 and 0.5, and strong when >0.5.  
 
Responsiveness 
a) Change over time. This is an assessment of whether measurements using the instrument can 
detect a change over time, where a change is expected. This may be before and after an 
intervention, or through progression of a disease. Evidence was considered to be good where a t-
test was significant, though weaker evidence to support responsiveness was considered where there 
was a change in the expected direction, but was not statistically significant or not tested. Effect size 
and standardised response mean were also acceptable assessments of responsiveness.  
b) Ceiling and floor effects were also considered to be indicators of responsiveness. Assessments of 
ceiling effects include the proportion of patients who score full health within a group of patients 
with known health detriments. A ceiling or floor effect can affect the sensitivity of the measure in 
detecting changes over time in patients at the extremes of the measure (for example those with 
severe disease activity and those with just minor symptoms of the condition). 
 
3.2 Alternative measures (WP1.2) 
Searches were conducted to identify existing reports and guidelines relating to other measures that 
could be used in dementia, as the results of WP1.1 suggested that the EQ-5D was not appropriate 
for this condition. 
 
3.3 Evidence required for economic evaluations (WP1.3) 
The existing Health Technology assesments (HTAs) were reviewed alongside the variables currently 
collected in the NCA to determine if clinical or PROM data routinely collected in the NCAs would 
suffice to address questions of cost-effectiveness, and to identify any gaps in the evidence that 
would be required to compare providers, or the cost-effectiveness of interventions or policies. 
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4 RESULTS FOR DEMENTIA 
4.1 Evidence of appropriateness of EQ-5D in dementia (WP1.1) 
4.1.1 Selection of systematic review 
No selection was required as only one review was identified. The review was identified from the 
Longworth et al review.(1)  
 
4.1.2 Structured abstract for Hounsome et al 2010(2) 
Purpose of review 
The review aimed to summarise the existing evidence on the appropriateness of the EQ-5D in 
dementia. Within this wider aim, the feasibility, reliability and validity of the EQ-5D were examined 
although validity was mostly considered in light of convergence of self-reported and proxy (carers 
and clinicians) ratings.(2) 
 
Methods of review: Search and study selection: EuroQol, MEDLINE, CAREDATA, CAB direct, CINAHL, 
Cochrane library, Emerald, PsychInfo, and BIOSIS previews. Electronic searches were conducted from 
1990 to 2009, and used the terms  ‘Y- ? ? ?  ‘ĚĞŵĞŶƚŝĂ ? ? ‘ůǌŚĞŝŵĞƌ ?Ɛ ? (Alzheimers/Alzheimer)  ‘ƋƵĂůŝƚǇ 
of life ? ? A secondary search was conducted in Google Scholar, using the advanced option to search 
for articles including  ‘Ăůů the ǁŽƌĚƐ ? and  ‘ĞǀĞƌǇǁŚĞƌĞ in the ĂƌƚŝĐůĞ ? for  ‘Y-5D and ĚĞŵĞŶƚŝĂ ? and 
 ‘Y-5D and ůǌŚĞŝŵĞƌ ?Ɛ ? (Alzheimers/Alzheimer). However, the full search strategies were not 
reported and exact terms used in the research database searches were not provided. The review 
included studies that presented original research, used EQ-5D as the primary or secondary outcome, 
and were published in English.(2) 
 
Data extraction and synthesis: No details were provided on how data extraction was conducted. A 
narrative synthesis was performed, and all included studies were summarised in a tabular form in 
the paper. The psychometric properties of interest were i) feasibility, as assessed by completion 
rates and completion time ii) reliability, described as temporal stability (test-retest correlation) and 
internal consistency (correlation between items that measure the same domain), iii) responsiveness, 
defined as characterising the ability of the instrument to capture health changes over time, iv) 
construct validity, whether the instrument really measures HRQoL, v) criterion validity, whether 
scores on the instrument agree with gold standard measures, and vi) content validity, which was 
described as determining whether all the important aspects of the construct are covered.  
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Results of the review   
Hounsome et al 2010(2) included 21 articles describing 18 studies which reported evidence on the 
application/appropriateness of the EQ-5D, self or proxy-reported (carers or clinicians, as proxies) in 
dementia research. The tabulated summary of included studies reported sample characteristics, 
severity of cognitive impairment within the sample, subject of assessment (patients and/or carers), 
mode of assessment (self-report or proxy report), findings and conclusions. The review results were 
presented for feasibility, validity, and for the use of EQ-5D with carers. 
Self-report was examined in 4 studies, and included the assessment of acceptability (through 
completion rates) and time spent completing the questionnaires. High completion rates were 
reported for patients with mild dementia (according to Mini-mental State Examination (MMSE) or 
the Clinical Dementia Rating (CDR)), but lower rates were reported in patients with moderate and 
severe dementia (13% to 63% depending on the study).(3-6) In two studies, feasibility was also 
assessed by examining completion times of EQ-5D by patients, with average values ranging from 4.1 
to 15.3 minutes to complete the questionnaire.(5;7) Two studies examined the feasibility of EQ-5D 
proxy-scores, and found that more than 90% of carers completed the questionnaire and that the 
mean time for completion was 2.3 minutes.(7;8) 
Results were presented for overall validity, rather than for each validity-related psychometric 
property. Some evidence of potential ceiling effects was found in three studies where more than a 
ƚŚŝƌĚ ŽĨ ƉĂƚŝĞŶƚƐǁĞƌĞ Ăƚ ƚŚĞ ŚŝŐŚĞƐƚ ůĞǀĞů ŽĨ ƌĞƐƉŽŶƐĞ  ? ‘ŶŽ ƉƌŽďůĞŵƐ ? ? ĨŽƌ ƐĞǀĞƌĂů Žƌ ĂůůŽĨ Y-5D 
health domains.(3;4;7) This ceiling effect was not observed for other generic measures, namely 
Quality of Well Being (QWB) and Health Utility Index (HUI).(7) Two studies examined correlation 
between patient rated EQ-5D score and disease specific health related quality of life (HRQoL) 
measures, which included the Quality of Life  W ůǌŚĞŝŵĞƌ ?Ɛ ĚŝƐĞĂƐĞ  ?YŽ>-AD) and the Dementia 
Quality of Life instrument (DQoL). One study found strong correlations between EQ-5D index scores 
and the two measures (QoL-AD: r=0.72; DQoL: r=0.63; n=24),(9) while the other study found lower 
but still strong correlation between EQ-5D scores and  QoL-AD (QoL-AD: r=0.72; DQoL: r=0.51; 
p<0.001; n=not clear).(10)  It is worth mentioning that there was one other study (not mentioned in 
the narrative synthesis), where no association was found between EQ-5D scores (unclear if ratings 
were performed by patients, carers or both) and MMSE (p=0.16).(3) Another study was said to have 
found no correlation between patient rated EQ-5D domains and dementia severity, except for a 
positive association between the anxiety/depression and MMSE.(5) Construct validity was assessed 
for different type of proxies, namely clinicians and carers, by examining correlations between EQ-5D 
health dimensions aŶĚƐĐŽƌĞƐŽĨŽƚŚĞƌ ŝŶƐƚƌƵŵĞŶƚƐ ?KŶĞƐƚƵĚǇ ĨŽƵŶĚĐůŝŶŝĐŝĂŶƐ ? ƌĂƚŝŶŐs had higher 
EEPRU NCA Appendix J: Dementia 
Page 10 
 
construct validity for more observable domains (mobility and self-care), while carers had higher 
construct validity for less observable dimensions (usual activities and anxiety/depression). The 
correlation of EQ-5D usual activities dimension with the Bristol Activities of Daily Living scale was 
strong for clinicians (r=0.87; p<0.01; n=64), and the correlation of the anxiety/depression dimension 
with the Neuropsychiatric Inventory was also strong for carers (r=0.57; p<0.01; n=64).(10) Another 
ƐƚƵĚǇ ĞǆĂŵŝŶĞĚ ƚŚĞ ůĞǀĞů ŽĨ ĂŐƌĞĞŵĞŶƚ ďĞƚǁĞĞŶ ĐĂƌĞƌƐ ? ĂŶĚĐůŝŶŝĐŝĂŶƐ ? ƌĂƚŝŶŐƐ ŽĨ Y-5D, and 
reported poor agreement between these two proxies for the pain/anxiety health dimension. The 
kappa statistics were reported to be lower than 0.5 between patients, carers and physicians, as well 
as between carers and physicians for all dimensions except mobility.(4) 
The assessment of content validity was based on two studies, which identified attributes considered 
by patients to be part of HRQoL and compared these to the attributes of EQ-5D and other generic 
measures (QWB and HUI), to verify whether these were included. The following attributes were 
mentioned by dementia patients, and were not present in EQ-5D: sleep disturbances, burden of 
memory loss, disorientation in space, lack of interest and motivation, lack of exercise, concerns over 
medication, contact with family members, opportunity to travel, and religion.(7;11) 
The authors claim that several studies demonstrated the feasibility, reliability and validity of proxy 
ratings of the EQ-5D, and report mean proxy rated EQ-5D utilities for patients at different severity 
levels (mild dementia:0.69; severe dementia:0.33),(6) and for dementia patients compared to the 
general population (0.27 vs. 0.70).(12) These studies also reported strong correlations between EQ-
5D proxy ratings and patient cognitive function.(6)  
 
ZĞǀŝĞǁĂƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ 
The authors of the review concluded that the EQ-5D performance in dementia studies is comparable 
to other generic utility instruments. They also concluded that EQ-5D is more reliable than other 
utility instruments in patients with mild dementia. The authors advise caution when selecting proxy 
respondents, given poor agreement of ratings between different proxies, and between patients and 
proxy respondents. Finally, they state that there are some concerns about the validity of EQ-5D in 
studies in moderate to severe dementia, but the EQ-5D still remains useful especially in conjunction 
with robust dementia specific quality of life-measures. 
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Assessment of review in relation to objectives of work package 1.1 
Relevance of review question: Although the overall purpose of the review was partly convergent 
with the aims of WP1.1 for dementia, a greater focus was placed in assessing validity of EQ-5D in 
terms of convergence between self-reported and proxy ratings of the instrument.  This is however 
an important issue in dementia, as ŚŝŐŚĞƌ ůĞǀĞůƐŽĨĐŽŐŶŝƚŝǀĞ ŝŵƉĂŝƌŵĞŶƚŵĂǇŚŝŶĚĞƌ ƚŚĞƉĂƚŝĞŶƚ ?Ɛ
ability to self-report.  
Assessment of review quality: Hounsome et al. (2011)(2) scored poorly against the relevant 
Assessing the quality of systematic reviews (AMSTAR) criteria. It was unclear whether an a priori 
design was used, as no reference was made to it within the review. Although study characteristics 
were reported, no mention was made regarding whether a quality assessment of studies was 
conducted, and therefore, this was not taken into account when formulating conclusions. The 
process of data extraction and data checking was not described, and the number of reviewers 
involved in this process was not reported. 
 
Acceptability of the search: The review authors conducted searches in a wide range of databases. 
The described method of concept combination and terms used was appropriate to the review in 
topic.  
 
Acceptability of study selection: The selection criteria were succinctly described and appeared to be 
in accordance with the aims of WP1.1.  
 
In summary, although there are some positive results, in general, Hounsome provides sufficient 
evidence to raise concerns relating to the appropriateness of EQ-5D in patients with dementia.  A 
ceiling effect was observed in three studies,(3;4;7) two studies reported the EQ-5D may not be 
acceptable for patients with severe dementia,(4;5) and two studies reported no relationship 
between self-reported EQ-5D scores and clinical measures.(3;6) Conversely two of three studies 
reported there was a relationship between proxy scores and clinical variables.(3;13) However, 
several issues with proxy scores were also described. Six studies reported no relationship between 
self-reported and proxy scores (even in patients with mild dementia).(3;5-7;14;15) Patients scored 
ŚŝŐŚĞƌ,ZYŽ>ƚŚĂŶƉƌŽǆŝĞƐ ŝŶƚŚŽƐĞƚŚĂƚƉƌŽǀŝĚĞĚƚŚŝƐ ŝŶĨŽƌŵĂƚŝŽŶĂŶĚƚŚĞĐĂƌĞƌƐ ?ƌĞƐƉŽŶƐĞƐǁĞƌĞ
influenced by the level of dependency of the patient.(6;7;15) In addition, three studies reported no 
association between clinician and carer-proxy scores, with evidence suggesting that each may have a 
more accurate concept of particular attributes of HRQoL.(4;5;10) 
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Table 1: Summary of evidence on EQ-5D for dementia 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
Self-reported 
EQ-5D (17) Good for 
mild 
dementia. 
Poorer for 
moderate to 
severe 
dementia. 
- Mixed; Poor - Evidence 
of ceiling 
effects 
Proxy-rated 
 EQ-5D  (19) Good - Some positive 
evidence, but 
methods have flaws; 
Fair. 
- Evidence 
of ceiling 
effects 
 Concerns about appropriateness.  
 
 
4.2 Alternative measures in dementia (WP1.2) 
4.2.1 Other measures for dementia  
Twelve documents were identified by the initial searches as described in Appendix B. Two 
documents described standards of care for patients with dementia, with the latter focusing on 
setting the standards of care against which the dementia NCA results would be compared(16;17).  
Four other documents were reports, two describing the results of two audits, one conducted in 
memory clinics in England,(18) another on the first round of the dementia NCA.(19) Two of the 
reports were produced by ƚŚĞůǌŚĞŝŵĞƌ ?ƐƐŽĐŝĞƚǇ ?ŽŶĞǁĂƐĂĐŽƐƚŝŶŐƌĞƉŽƌƚ ?ǁŚŝůĞƚŚĞŽƚŚĞƌĐŽůĂƚĞĚ
evidence on the experiences and outcomes of providing dementia care in the community.(20;21)  
The search also identified a carer/patient questionnaire applied in the first round of the dementia 
NCA;(17) a document describing how to integrate geriatricians in an integrated pathway of dementia 
care;(22) and another document which provided guidance on the provision of services by general 
practioners with special interests in dementia.(23)  None of these documents presented evidence on 
the use of PROMs in dementia, and were thus excluded from the review, leaving two potentially 
relevant documents. One document was an European Medicines Agency (EMA) guideline on the 
ĐůŝŶŝĐĂů ŝŶǀĞƐƚŝŐĂƚŝŽŶ ŽĨ ŵĞĚŝĐŝŶĂů ƉƌŽĚƵĐƚƐ ŝŶ ƚŚĞ ƚƌĞĂƚŵĞŶƚ ŽĨ WĂƌŬŝŶƐŽŶ ?Ɛ ĚŝƐĞĂƐĞ ? ŝŶĐůƵĚŝŶŐ ƚŚĞ
treatment of cognitive disfunction (dementia) in this pathology. This document states that efficacy in 
WĂƌŬŝŶƐŽŶ ?Ɛ ĚŝƐĞĂƐĞ ĚĞŵĞŶƚŝĂ ƐŚŽƵůĚ be demonstrated on cognition and activities of daily living 
(ADL), but makes no recommendations on instruments to measure it, and refers to the D ?Ɛ
ŐƵŝĚĂŶĐĞ ŽŶ ůǌŚĞŝŵĞƌ ?Ɛ ĚŝƐĞĂƐĞ ?(24)  The other relevant document corresponded to guidance on 
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ŵĞĚŝĐŝŶĂůƉƌŽĚƵĐƚƐĨŽƌƚŚĞƚƌĞĂƚŵĞŶƚŽĨůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞĂŶĚŽƚŚĞƌĚĞŵĞŶƚŝĂƐ ?ǁŚŝĐŚĚĞƐĐƌŝďĞƐĂ
number of instruments that can be used to demonstrate treatment efficacy without recommending 
any single instrument. Thus, the guideline states that applicants must justify the instruments 
selected with respect to their psychometric properties and the population studied (defined by type 
of dementia).(25) 
 
The EMA guideline on dementia recommended the use of the following types of instruments to 
assess efficacy: objective cognitive tests; measures of self care and activities of daily living; global 
assessment of change; measures of HRQoL; and behavioural signs and symptoms.  It was highlighted 
that in general, self-report measures tended be less sensitive to treatment effects than observer 
related instruments, particularly in moderate to severe disease stages, and recommended the 
involvement of relatives or nurses in the assessment.(25) The guideline stated that measures of 
HRQoL cannot be specifically recommended for regulatory purposes in dementia due to insufficient 
validation of its assessment in this condition ? dǁŽ ĚŝƐĞĂƐĞ ƐƉĞĐŝĨŝĐ ŝŶƐƚƌƵŵĞŶƚƐ ? ƚŚĞ ůǌŚĞŝŵĞƌ ?Ɛ
Disease-Related QOL (ADRQL) and the QOL-ůǌŚĞŝŵĞƌ ?Ɛ ŝƐĞĂƐĞ  ?YK>-AD) were said to have 
sufficient psychometric properties with ongoing studies in responsiveness to clinical change. 
Nevertheless, the guideline recommended that similar instruments be developed for other forms of 
dementia.(25) Overall, the guideline provided very sparse information on the psychometric 
properties of the different outcome measures. Most measures that were said to be validated were 
specific ĨŽƌ ůǌŚĞŝŵĞƌ ?Ɛ ĚŝƐĞĂƐĞ ? ǁŝƚŚ ĞǆƚĞŶƐŝŽŶ ƚŽ ŽƚŚĞƌ ƚǇƉĞƐŽĨ ĚĞŵĞŶƚŝĂ ƌĞƋƵŝƌŝŶŐ ĨƵƌƚŚĞƌ
validation studies. The guideline also identified issues with the appropriateness of instruments at 
different disease severity levels, and recommended that disease severity was taken into account 
when selecting instruments.(25) 
 
In addition to the documents described in the previous paragraph, evidence presented in two 
manuscripts known to the authors is worthy of consideration.(26;27) Whilst these sources are of 
relevance, it should be noted that they were not found through a systematic search process, and 
consequently all relevant evidence may not have been identified.   
 
The first source of evidence is a validation study of a bolt-on for cognitive impairment developed for 
the EQ-5D (EQ-5D+C).(26) Patients are asked to select betweĞŶ “/ŚĂǀĞno impairment of cognitive 
functioning ? ? “/ŚĂǀĞƐŽŵĞimpairment of cognitive functioning ?ĂŶĚ  “/ŚĂǀĞƐĞǀĞƌĞimpairment of 
cognitive functioning ? ? ǁŝƚŚ ĐƵĞƐ ƉƌŽǀŝĚĞĚ ƚŽ ĐŚĂƌĂĐƚĞƌŝƐĞ ƚŚĞ ĐŽŐŶŝƚŝŽŶ ĂƚƚƌŝďƵƚĞ  ?ĚĞƐĐƌŝďĞĚ ĂƐ
including memory, concentration, coherence, Intelligence Quotient).(28) The impact of responses on 
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the valuation of health states has been tested in an exploratory study.(26) The cognitive impairment 
bolt-on has been shown to significantly impact on at least some health states, with complex 
interplay between severity of the cognitive impairment response, and severity of responses in the 
other dimensions, and increases the variance of the valuations. The authors concluded that overall 
the proxy-rated EQ-5D+C performed similarly to the EQ-5D, and although they did not recommend 
its use in isolation, they stated that comparison of the utility scores obtained with the two 
instruments could give insight on whether cognition has a significant impact on utility.(26) 
 
The second source of evidence is a HTA report that aimed to develop health-state classifications for 
two dementia specific HRQoL instruments, the DEMQOL and the DEMQOL-proxy, so as to generate 
health states amenable to valuation and thus a preference-based tariff. The study also aimed to 
examine whether the utility values elicited from the general population differed from the utility 
values elicited from patients and carers for dementia health states generated for the classification 
system, and finally to examine the psychometric properties of dementia-specific preference-based 
measures.(27) The two resulting measures were named DEMQOL-U and the DEMQOL-proxy-U, and 
their validity (convergent and known-group), patient/proxy agreement and responsiveness to 
change were compared to EQ-5D and non-preference based measures using trial data. The data 
used to assess the psychometric properties of the instruments was from a study on the use of 
antidepressants for depression in dementia (n=236). There was evidence for the acceptability of the 
DEMQOL system, but missing data rates are higher than for EQ-5D. However, the DEMQOL utility 
measures appeared to be less affected by ceiling effects than the EQ-5D. The preference-based 
measures (DEMQOL, self-reported and proxy, and EQ-5D) were mostly in agreement, except for the 
lowest levels of utility. Mixed results were found for agreement between patient and carer reports 
over time, and low intraclass correlations were found throughout. Evidence regarding convergent of 
the DEMQOL-U system was also mixed, with these instruments having higher (but moderate) 
correlations with the Cornell Scale for Depression in Dementia than EQ-5D or the original DEMQOL. 
However, correlations between DEMQOL-U and the EQ-5D and the indicators of cognition, daily 
activities and behavioural disturbances were low. There was also no clear pattern to the DEMQOL 
utility measures or the EQ-5D across cognitive impairment and depression severity groups (known-
group validity). The DEMQOL-U performed better than DEMQOL-Proxy-U, but the proxy (carer) rated 
EQ-5D performed better than the self-reported EQ-5D. In terms of responsiveness, the DEMQOL 
utility measures and the EQ-5D did not perform as well as the original DEMQOL and DEMQOL-Proxy. 
In conclusion, the study provided early positive evidence of acceptability, validity and responsiveness 
of the DEMQOL-U and DEMQOL-proxy. The authors caution that further research should be 
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conducted using other datasets incorporating a range of clinical indicators and dementia severity 
levels.(27) 
 
4.3 Evidence for economic evaluations in dementia (WP1.3) 
4.3.1 Cost-effectiveness modelling approach used in recent HTAs in dementia 
Three technology appraisals (TAs) relating to dementia were identified from the searches, one of 
these has been suspended, and another has been superseded by a subsequent TA.(29) Only one TA 
was thus considered relevant, TA217 (Table 2).  This TA was a multiple technology appraisal (MTA) 
which assessed the clinical and cost-effectiveness of anti-dementia medication (acetylcholinesterase 
inhibitors, i.e. donezepil, galantamine and rivastigmine, and memantine) compared to each other 
ĂŶĚ ďĞƐƚ ƐƵƉƉŽƌƚŝǀĞ ĐĂƌĞ  ?^ ? ĨŽƌ ƚŚĞ ƚƌĞĂƚŵĞŶƚ ŽĨ ůǌŚĞŝŵĞƌ ?Ɛ ĚŝƐĞĂƐĞ ? cetylcholinesterase 
inhibitors ĂƌĞŝŶĚŝĐĂƚĞĚĨŽƌŵŝůĚƚŽŵŽĚĞƌĂƚĞůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ?ǁŚŝůĞŵĞŵĂŶƚŝŶĞŝƐŝŶĚŝĐĂƚĞĚĨŽƌ
moderate to severe forms of the condition.(30) 
 
The MTA used a Markov model with three discrete health states defined by institutionalisation and 
survival status (pre-institutionalisation, institutionalisation and death).(30) The natural disease 
history was modelled by two multivariate regression time to event models (time to 
institutionalisation and time to death), which predict events based on age, cognition (measured by 
MMSE) and functional ability (measured by ADL). Cohorts entered the model 4.9 years after disease 
diagnosis, based on patient population characteristics reported in the UK observational study that 
informed natural history of the disease in the model, with treated cohorts starting treatment at 
model entry.  For the initial treatment period, mean time to institutionalisation and mean time to 
death are predicted using mean baseline characteristics of the cohort. After the initial treatment 
period, any treatment effects are assumed to have occurred, and so from that point onwards, mean 
time to institutionalisation is predicted based on the mean baseline characteristics plus the mean 
treatment effect for the treated cohorts. For example, if a mean baseline MMSE of 17 and a mean 
treatment effect of 0.5 on the MMSE scale are assumed, the mean time to institutionalisation for an 
untreated cohort would be predicted using a mean MMSE of 17. Mean time to institutionalization 
for a treated cohort is based on a mean MMSE of 17 for the initial treatment period, but would be 
based on a mean MMSE of 17.5 from the end of initial treatment onwards. Treatment effect was 
applied as the (weighted) mean difference in MMSE and Alzheimer Disease Cooperative Study ADL 
scale (ADCS-ADL) from randomised clinical trials (RCTs) to the baseline estimates of MMSE and 
ADCS-ADL used in the BSC cohort. Thus treated cohorts had a delay in institutionalisation compared 
to BSC. dŚĞŵŽĚĞůŝŵƉůŝĐŝƚůǇĂƐƐƵŵĞĚƚŚĂƚŝŶƐƚŝƚƵƚŝŽŶĂůŝƐĂƚŝŽŶǁĂƐĞƋƵŝǀĂůĞŶƚƚŽƐĞǀĞƌĞůǌŚĞŝŵĞƌ ?Ɛ
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disease (MMSE < 10), and did not allow transition from the institutionalisation to the pre-
institutionalisation state. The base-case analysis assumed that treatment effect had no impact in 
survival, while sensitivity analysis included a treatment effect on survival modelled through the 
impact of treatment on MMSE and ADL.(30) 
 
The model quality adjusted survival by assigning mean utility values to the discrete health states. 
While for the institutionalisation state a single utility estimate (corresponding to mean EQ-5D score 
for patients of MMSE lower than 10) was applied to patients, utility in the pre- institutionalisation 
state depended on MMSE range and time to the end of institutionalisation. Utilities in the base-case 
analysis were derived from mean EQ-5D estimates sourced from external estimates reported in the 
published literature, and were carer proxy ratings. (30) 
 
Table 2: Summary of existing model used in dementia TAs 
 Model approach Method used to model utilities  
MTA (TA217): Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (replaces 
TA111); 2011 (30) 
 TAG Markov model; three discrete health 
states: pre-institutionalisation, 
institutionalisation and death 
Effectiveness: 
Disease progression (time to 
institutionalisation and time to death) was 
based on a multivariate regression time to 
event models 
Model covariates included age, MMSE and 
ADL. The proportion of patients in pre- 
institutionalisation state and 
institutionalisation state at model entry 
depended on disease severity and was 
estimated from a separate observational 
study. Treatment effect estimated by 
weighted mean differences in MMSE and 
ADL applied to the baseline estimate of 
MMSE and ADL used in the BSC cohort. 
Sources: UK observational studies; clinical 
RCTs (treatment effects). 
Utility: 
Patient utility (rated by carer-proxy in the base-
case, and self-rated for sensitivity analysis): 
For the EQ-5D utility scores by MMSE ranges 
mapped onto time to the end of pre-
institutionalisation, so as to allow for 
heterogeneous HRQoL in pre- institutionalisation 
state. Single utility estimate for institutionalisation 
state, corresponding to mean EQ-5D utility score for 
patients with a MMSE score lower than 10. 
ĂƌĞƌ ?ƐƵƚŝůŝƚǇ (included in sensitivity analysis): 
HUI2 utility scores by MMSE ranges (severity 
measured in the CDR scale and mapped onto the 
MMSE scale) mapped onto time to the end of pre-
institutionalisation.  
Source: Published literature for utility estimates; 
MMSE scores at varying times to the end of pre-
institutionalisation data from UK observational 
study. 
AE: Adverse Events; MTA: Multiple Technology Appraisal; STA: Single Technology Appraisal; MI: 
Myocardial Infarction; TAG: Technology Appraisal Group; TA: Technology Appraisal; RCT: randomised 
controlled trial; RR: Relative risk; MMSE: Mini-mental state examination; ADL: Uniform activities of daily 
living; CDR: Clinical dementia rating scale. 
 
In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for dementia: 
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x Dementia diagnosis  
x MMSE score 
x ADL score 
x Full-time institutionalisation 
x Drug therapy administered (type of intervention) 
x Utility values (patient and/or carer) 
x Death rates 
The majority of this evidence would need to be dated and linked through timings of collection. 
 
4.3.2 Fields collected in National Audit of Dementia 
The National Audit of Dementia (NAD) in its second and latest round (2012-2013) consisted of two 
modules, the hospital organisational checklist, and the casenote audit. The hospital organisational 
checklist is focused on structures, policies, care processes and key staff that impact on service 
planning and provision for care of people with dementia within a general hospital. The casenote 
audit consists of a sample of a minimum of 40 patients with a diagnosis or current history of 
dementia per hospital, which is audited against a checklist of standards that relate to their 
admission, assessment, care planning/delivery, and discharge. Participation in the NAD was open to 
all general acute hospitals, or those providing general acute services on more than one ward, in 
England and Wales. Data in the hospital organisational checklist is collected through the 
 ‘KƌŐĂŶŝƐĂƚŝŽŶĂůŚĞĐŬůŝƐƚ ?ƚŽŽů ?ĂŶĚƚŚĞĐĂƐĞŶŽƚĞĂƵĚŝƚĚĂƚĂǁĂƐĐŽůůĞĐƚĞĚƚŚƌŽƵŐŚƚŚĞ ‘ƵĚŝƚŽĨĂƐĞ
EŽƚĞƐ ?ƚŽŽů ?dŚĞĐĂƐĞŶŽƚĞĂƵĚŝƚǁĂƐĂƌĞƚƌŽƐƉĞĐƚŝǀĞĂƵĚŝƚof the records of patients with a diagnosis 
of dementia discharged from a given hospital between 1 September 2011 and 29 February 2012 (for 
the current round of the audit). The fields collected via both tools are listed in the Appendix. 
 
Overall the audit provides data that allows comparing the standard of treatment and care in 
dementia between participating hospitals, and for the same hospital for different periods in time (by 
comparing results between rounds of the audit). These data are grouped by the following themes: 
governance; assessments; antipsychotic prescription: protocol and practice; liaison psychiatry 
services; hospital discharge and transfers; information and communication; and staff training. The 
ultimate objective of the audit is to improve the quality of care and support of people with dementia 
and frailer older people who are admitted to hospital for acute treatment.(18) 
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The first round of the audit (2010-11) alsŽŝŶĐůƵĚĞĚ ‘ĞŶŚĂŶĐĞĚĂƵĚŝƚƚŽŽůƐ ? ?ǁŚŝĐŚǁĞƌĞŶŽƚĐŽůůĞĐƚĞĚ
for the second round of the audit. These components did not collect any PROM data (or other 
outcome measures), and included: 
x ward organisational checklist concerning staffing, support and governance at a ward level; 
x a ward environmental checklist - information about aspects of the ward physical 
environment known to impact on people with dementia; 
x staff questionnaires to gather feedback from ward staff about awareness of dementia and 
about support offered to patients with dementia on their ward; 
x carer/patient questionnaire that evaluates carers ?experience of the support received from 
ǁĂƌĚƐƚĂĨĨĂŶĚƉĂƚŝĞŶƚƐ ? overall perception of the quality of care on the ward; observation of 
care interactions to evaluate the quality of the hour-to-hour provision of care to people with 
dementia.(19) 
 
4.3.3 Comparing fields in the National Audit of Dementia with variables used in existing HTAs 
dŚĞdŽŶůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ(30) used survival analysis to model mortality and disease progression. 
The audit collects data on in-ŚŽƐƉŝƚĂůĚĞĂƚŚ ?ĂƐǁĞůůĂƐƉĂƚŝĞŶƚ ?ƐĂŐĞǁŚŝĐŚǁĂƐĂĐŽǀĂƌŝĂƚĞŝŶ ƚŚĞ
regression models used to predict mortality, and time to institutionalisation in the economic model. 
However, the NAD does not collect data on the two other covariates in both regression models, i.e. 
ŵĞĂƐƵƌĞƐ ŽĨ ĐŽŐŶŝƚŝŽŶ ĂŶĚ ƉŚǇƐŝĐĂů ĂďŝůŝƚǇ ? dŚĞƌĞ ĂƌĞ ƚǁŽ ĨŝĞůĚƐ ŽŶ ƚŚĞ ĐĂƐĞŶŽƚĞ ĂƵĚŝƚ  ? ‘Place of 
Living or Care before Admission ? ?  ‘Place of Living or Care after Discharge ? ? ƚŚĂƚ ƉƌŽǀŝĚĞ ƐŽŵĞ
information on whether the patient was institutionalised before and/or after hospital admission. The 
only treatment data collected by the audit refers to the use of antipsychotic drugs, which are not 
anticipated to impact on disease progression, but may reduce behavioural and psychological 
ƐǇŵƉƚŽŵƐ ? ‘ŝƐƚƌĞƐƐ ?ĂŐŝƚĂƚŝŽŶĂŶĚďĞŚĂǀŝŽƵƌƚŚĂƚĐŚĂůůĞŶŐĞƐ ?) fields (Appendix). 
 
Data collection within the NAD has the objective of allowing comparisons between hospitals in terms 
of standard of treatment and care provided to dementia patients. The focus of the audit is mostly on 
describing the treatment, care and support of these patients. Although this is valuable information, 
the audit in its current format does not collect any variable that can be used to derive utility 
estimates, directly or indirectly (e.g. through a mapping function). To our best knowledge the 
collection of any PROMs within the NAD is not currently being considered. 
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4.4 Recommendations for dementia 
Based on the evidence reviewed, the EQ-5D is not thought to be appropriate for patients with 
dementia.  It is not believed that there are data in the dementia NCA which could be used to inform 
the HRQoL associated with the condition, either directly through a preference-based measure, or 
indirectly through a surrogate.  In addition, it is not believed that the other variables collected in the 
audit will suffice to conduct robust economic evaluations.  Potential recommendations (PR) and 
areas for future research (FR) are discussed below.  All suggested future research areas are 
indicative and would require a discussion and detailed proposal if required. 
 
Based on previous modelling approaches, it is recommended that MMSE and ADL scores are 
collected in the NCA, to inform disease progression in models. However, these measures are not 
preference-based and cannot be used to generate quality adjusted life years (QALYs) in economic 
evaluations. The review in Section 4.2 identified two dementia specific preference-based measures, 
the DEMQOL-U and the DEMQOL-U-proxy, that should be collected in the audit alongside cognition 
and functional ability measures (for example, MMSE and ADL) (PR.1). The assessment of the 
psychometric properties of these measures has provided some early evidence that they might be 
suitable to inform cost-effectiveness analysis in dementia, but further research is necessary to 
ascertain their construct validity and responsiveness to clinical change. The dementia NCA data can 
be used to assess the psychometric properties of the DEMQOL-U and the DEMQOL-U-proxy, if these 
are collected alongside clinical measures, such as the MMSE and ADL (FR.1). 
 
The dementia audit does not currently collect suffient detailed information to compare providers or 
perform economic evaluations.  The inclusion of mandatory information on time and date of full-
time institutionalisation, type of drug therapy administered, death and utility values would increase 
the flexibility of the secondary use of the data (PR.2).   
 
Table 3: Recommendations and associated future research for dementia 
PR.1 Collect the DEMQOL-U and the DEMQOL-U-proxy in a service user questionnaire alongside 
clinical measures such as the MMSE and ADL. 
FR.1 Assess the appropriateness of the DEMQOL-U and the DEMQOL-U-proxy in dementia 
patients using the data from the NCA 
PR.2 Collect mandatory information on time and date of full-time institutionalisation, type of 
drug therapy administered, death and utility values. 
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5.  SUMMARY   
5.1 Summary of evidence used to inform the conclusions for WP1.1 and WP1.2 
An existing review provided evidence that there are some concerns relating to the use of the EQ-5D 
in dementia, including ceiling effects, and a lack of relationship between self-report and clinical 
measures. This review focussed some attention on the convergent validity between self-report and 
proxy-report, showing there was no relationship between self and proxy reports even in mild 
disease, and no association between carer-proxy and clinician scores, perhaps due to each having 
better insight in different attributes. Other measures were considered in two guidelines, and two 
reports known to the authors. It is recommended that two dementia-specific preference-based 
measures, the DEMQOL-U and the DEMQOL-U-proxy, should be collected in the audit alongside 
cognition and functional ability measures (see summary for WP1.3) 
 
Table 4: Summary of evidence currently available for recommended measure(s) 
Measure N Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change  
over 
time 
Ceiling  
Effect 
EQ-5D 21 Mixed NR Mixed Poor NR Poor Not appropriate 
DEMQoL-U         
  These measures (patient and proxy rated) provided early positive evidence of 
acceptability, validity and responsiveness, but require further validation in datasets 
incorporating a range of clinical indicators and dementia severity levels. 
N= number of studies used to inform conclusions, KGV: known group validity; NR, the existing review did not 
review this psychometric property. 
 
5.2 Summary of evidencerequired for use in economic evaluations (WP1.3) 
In its latest round, the dementia audit does not include a service user or carer questionnaire and 
thus no PROMs are currently collected.  The information collected in the audit would enable 
comparison of providers (i.e. hospitals) in terms of the standard of treatment and care provided to 
patients with dementia, and to compare the performance of the individual hospital over time.  
However, it is not clear if the data could be case-mixed using variables such as cognition and physical 
ability.  In addition to evidence on HRQoL, to conduct formal economic evaluations, the audit would 
require additional detailed mandatory information such as dementia diagnosis, MMSE score, ADL 
score, type of pharmaceutical therapy administered and death rates. 
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7.  APPENDIX 
 
The tables in this Appendix provide additional information for the reviews (WP1.1 and 1.3) conducted for dementia.  
Table A1: Characteristics of studies in the systematic review for dementia (WP 1.1) 
Study ref 
Author, Year  
Country  Disease/treatment stage Treatment 
(if any) 
Study type (e.g. cross 
sectional, RCT, cohort) 
Study objective 
Wolfs, 2008(31) The Netherlands Moderate dementia 
 
NR RCT NR 
Karlawish, 2008
a
(3) United States Mild to moderately severe dementia NR NR 
 
NR 
Boström, 2007(14) Sweden Mild to severe ůǌŚĞŝŵĞƌ ?Ɛ disease  and 
dementia with Lewy bodies 
NR NR 
 
NR 
Wolfs, 2007(26) The Netherlands Moderate dementia NR NR 
 
NR 
Jönsson, 2006
a(
6) Sweden, Denmark, Finland, Norway Mild to severe dementia NR NR NR 
Jönsson, 2006
b(
32) Sweden, Denmark, Finland, Norway Mild to severe dementia NR NR NR 
Naglie, 2006(7) Canada Mild to moderate dementia NR NR NR 
Vogel,2006 (15) Denmark Mild dementia NR NR NR 
Bryan, 2005(10) UK Mild to moderate dementia NR NR NR 
Selwood, 2005(9) UK Mild to moderate dementia NR NR NR 
Andersen, 2004(33)  Denmark Mild to severe dementia NR NR NR 
Ankri, 2003(5) France Mild to severe dementia NR NR NR 
Thorgrimsen, 
2003(34) 
UK Mild to severe dementia NR NR NR 
Coucill, 2001(4) UK Mild to moderately severe dementia NR NR NR 
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Silberfeld , 
2002(11) 
Canada Mild to moderate dementia NR NR NR 
Karlawish, 2008 
b
(8) United States Mild to moderate dementia NR NR NR 
Charlesworth, 
2008(8) 
UK Dementia/not indicated NR RCT NR 
Lopez-Bastida,  
2006(12) 
Spain Mild to severe dementia NR NR NR 
Dixon,  2006(35) UK Dementia/not indicated NR NR NR 
Andrén and 
Elmstahl, 2008(36) 
Sweden Mild to moderate dementia NR NR NR 
Serrano-Aguilar, 
2006(37) 
Spain Dementia/not indicated NR NR NR 
NR, Not reported; RCT, randomised clinical trial. 
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Table A2: Participant characteristics in studies in the systematic review for dementia (WP 1.1) 
Ref 
Man 
ID 
Study ref 
Author, Year 
Number of 
participants 
recruited 
Age in years 
mean (sd); 
range 
male 
%  
Ethnicity 
(%) 
Other characteristics (%) Missing data (patients completing study) 
include reasons for non-completion if 
given 
 Wolfs, 2008(31) Intervention: 137 
Control: 93 
Intervention: 
78.3 
Control: 77.3 
NR NR NR NR 
 Karlawish, 
2008
a(
3) 
93 77 NR NR NR NR 
 Boström, 
2007(14) 
ůǌŚĞŝŵĞƌ ?Ě
disease:34 
Dementia with 
>Ğǁŝ ?ƐďŽĚŝĞƐ P ? ?
ůǌŚĞŝŵĞƌ ?Ě
disease:78.2 
Dementia with 
>Ğǁŝ ?Ɛ
bodies:77.4 
NR NR NR NR 
 Wolfs, 2007(26) 196 77.8 NR NR NR NR 
 Jönsson, 2006
a
(6) 208 75.9 NR NR NR NR 
 Jönsson, 2006
b(38)
 208 75.9 NR NR NR NR 
 Naglie, 2006(7) 60 78.6 NR NR NR NR 
 Vogel,2006 (15) 48 77 NR NR NR NR 
 Bryan, 2005(10) 64 76 NR NR NR NR 
 Selwood, 2005(9) 24 81.5 NR NR NR NR 
 Andersen, 2004 
(33) 
211 78.1 NR NR NR NR 
 Ankri, 2003(5) 142 82.9 NR NR NR NR 
 Thorgrimsen, 
2003(13) 
Sample 1: 60 
Sample 2: 201 
Sample 1: 81 
Sample 2: 85 
NR NR NR NR 
 Coucill, 2001(4) 64 76 NR NR NR NR 
 Silberfeld , 
2002(11) 
20 79 NR NR NR NR 
 Karlawish, 2008 
b(
8) 
100 77 NR NR NR NR 
 Charlesworth, 
2008(39) 
Intervention: 116 
Control: 120 
Intervention: 79 
Control: 78 
NR NR NR NR 
 Lopez-Bastida,  
2006(12) 
237 75.5 NR NR NR NR 
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 Dixon,  2006(35) 64 80 NR NR NR NR 
 Andrén and 
Elmstahl, 
2008(36) 
130 61 NR NR NR NR 
 Serrano-Aguilar, 
2006(37) 
237 75.5 NR NR NR NR 
SD, standard deviation; NR, not reported;  
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Table A3: Valuation and descriptive methods used in studies in the systematic review for dementia (WP 1.1) 
 GENERIC MEASURES OTHER MEASURES USED 
Study ref 
Author, Year 
Descriptive 
system  
Tariff 
used  
Mean  
(SD); 
95% CI 
Condition-
specific 
HRQL 
measures  
Clinical 
measures  
Qualitative 
questions  
Missing data; completion rates of measures; etc.  
Wolfs, 
2008(31) 
EQ-5D 
 
NR NR None  MMSE NR NR 
Karlawish, 
2008
a
 (3) 
EQ-5D 
 
NR NR QoL-AD MMSE NR Self-reported EQ-5D: 99% completion rate 
HUI NR NR 
Boström, 
2007(14) 
 
EQ-5D 
  
NR NR QoL-AD MMSE NR NR 
Wolfs, 
2007(26) 
EQ-5D NR NR EQ-5D-C MMSE NR NR 
Jönsson, 
2006
a(
6) 
 
EQ-5D NR NR None MMSE NR Self-reported completion rate in patients with moderate to severe 
dementia :13% 
Overall completion rate:50% 
Jönsson, 
2006
b
 (38) 
 
EQ-5D NR NR None MMSE NR NR 
Naglie, 
2006(7) 
 
EQ-5D 
 
NR NR None MMSE NR NR 
HUI NR NR 
Naglie, 
2006(7) 
 
EQ-5D 
 
NR NR None MMSE NR NR 
HUI NR NR 
Vogel,2006 
(15) 
EQ-5D NR NR 
 
QoL-AD MMSE NR NR 
Bryan, 
2005(10) 
EQ-5D NR  NR 
 
NPI 
BALDS 
MMSE  NR NR 
Selwood, 
2005(9) 
 
EQ-5D NR NR QoL-AD 
Dementia 
QoL 
MMSE NR NR 
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Andersen, 
2004 (33) 
 
EQ-5D Mapped 
from 
ADL 
NR ADL MMSE NR NR 
Ankri, 
2003(5) 
EQ-5D NR NR None MMSE NR Completion rate in moderate to severe dementia:< 63% 
22% of patients gave no response 
Thorgrimsen, 
2003(13) 
EQ-5D NR NR QoL-AD 
Dementia 
QoL 
MMSE NR NR 
Coucill, 
2001(4) 
EQ-5D NR NR None CDR scale NR NR 
SF-12 NR NR 
Silberfeld , 
2002(11) 
EQ-5D NR NR  None MMSE NR 
NR 
NR 
HUI NR 
QWB NR 
Karlawish, 
2008
b
(8) 
EQ-5D NR NR QoL-AD 
IADL 
BADL 
MMSE NR NR 
SF-36 NR NR 
Charlesworth, 
2008(39) 
EQ-5D NR NR None NR NR NR 
Lopez-
Bastida,  
2006(12) 
EQ-5D NR Patient 
(self-
report): 
0.29 
Carers 
(proxy-
report): 
0.67 
None CDR scale NR NR 
Dixon,  
2006(35) 
EQ-5D NR NR None NR NR NR 
Andrén and 
Elmstahl, 
2008(36) 
EQ-5D None NR None MMSE NR NR 
Serrano-
Aguilar, 
2006(37) 
EQ-5D VAS None NR None NR NR NR 
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BADLS, Bristol Activities of Daily Living Scale; BADL, basic activities of daily living; CDR, Clinical Dementia Rating; EQ-5D+C, EQ-5D with a cognitive dimension; HUI, Health 
Utility Index; IADL, Instrumental Activities of Daily Living; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; QoL-AD, Quality of Life WAlzheimer's 
Disease; QWB, Quality of Well being. 
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Table A4: Acceptability, reliability and validity assessment in studies in the systematic review for dementia (WP 1.1) 
Author, Year Method of measuring validity 
Type of validity, how (e.g. known 
group/convergent)? 
Validity results 
Group A(n) vs. Group B(n)
Ƈ
 
Mean EQ-5D; mean difference in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ 
Karlawish, 2008
a
 (3) Known-group validity No association between EQ-5D and disease-
specific scores MMSE (P = 0.16). 
 
 Convergent validity No association between EQ-5D and QoL-AD (P 
< 0.01). 
 
 Convergent validity NR Lack of association between self- and proxy 
EQ-5D ratings. 
 Acceptability: % self-completion by severity 
class 
Mild dementia: 99% 
 
 
 Reliability: test-retest NR ĂƌĞƌƐ ?ƐƌĞƐƉŽŶƐĞŚĂĚŚŝŐŚĞƌƌĞůŝĂďŝůŝƚǇƚŚĂŶ
self-reported 
Boström, 2007(14) 
 
Convergent validity NR No correlation between proxy and self-
reported HR-QoL.  
Jönsson, 2006
a
(6) 
 
Known-group validity NR No correlation between MMSE and patient-
reported EQ-5D scores for mobility, 
pain/discomfort, and anxiety/depression. 
Discrepancy between patient and proxy 
ratings, even in the mild stage of dementia. 
 Acceptability: % self-completion by severity 
class 
Moderate to severe dementia :13% 
Overall completion rate:50% 
 
Naglie, 2006(7) 
 
Reliability Mean patient self-reported EQ-5D scores were 
significantly higher than mean proxy scores (P 
< 0.0001). 
Proxy ratings did not accurately reflect patient 
self-ratings.  
 Convergent validity NR EQ-5D score has strong correlation with QWB 
and HUI 
 Reliability: test-retest NR VAS unreliable in patients with mild and 
moderate dementia. 
EEPRU NCA Appendix J: Dementia 
Page 29 
 
 Feasability: Average completion time Patients: 15.3 minutes 
Carers:2.3 
 
 Feasability: % self-completion Carers: 90%  
Vogel,2006 (15) Convergent validity 
 
NR Lack of correlation between self- and proxy 
ratings. Patients reported significantly higher 
EQ-5D scores for mobility, self-care, and usual 
activities compared to proxies (P < 0.001). 
Bryan, 2005(10) Construct validity: correlation between 
specific domains of EQ-5D and disease 
specific measures 
Usual activities and BALDS (clinicians): r = 0.87, 
P < 0.01 
 
Anxiety/ depression and NPI (carers): r = 0.57, 
P < 0.01 
Data provided by clinicians had higher 
construct validity for more observable EQ-5D 
domains. Data provided by carers had higher 
construct validity for less observable domains.  
Selwood, 2005(9) 
 
Convergent validity: correlation of EQ-5D 
scores with those of QoL-AD and dementia 
QoL 
QoL-AD: r = 0.72, P < 0.01 
dementia QoL: r = 0.63, P < 0.01 
EQ-5D correlated with QoL-AD and dementia 
QoL. 
Ankri, 2003(5) 
 
Reliability: agreement between different 
raters (kappa statistics) 
Patients and carers: Kappa < 0.5 for all 
domains except mobility. 
Family and institutional carers: Kappa < 0.5 for 
all domains except mobility. 
Poor agreement between dementia patients 
and carers, as well as between family and 
institutional carers, except for mobility 
domain. VAS had poor reliability for dementia 
patients 
 Acceptability: % self-completion by severity 
class 
Moderate to severe dementia:< 63% 
22% of patients gave no response 
The severity of dementia influences 
acceptability of EQ-5D in patients. 
 Feasability: Average completion time 4.1 minutes  
 Known-group validity NR No correlation between patients rated EQ-5D 
domains and dementia severity, except for a 
positive association between the 
anxiety/depression and MMSE. 
Thorgrimsen, 2003(13) 
 
Convergent validity: correlation of EQ-5D 
and QoL-AD scores 
R=0.54, p<0.001 EQ-5D scores reported by patients correlated 
with QoL-AD scores.  
 Content validity Participants indicated more HRQOL attributes 
than included in EQ-5D (e.g., boredom, 
loneliness, loss of role, food and drinks) 
 
Coucill, 2001(4) Reliability: agreement between different 
raters (kappa statistics) 
Patients, carers and physicians: Kappa < 0.5 for 
all domains except mobility.  
Weak agreement between patients, carers 
and physicians and between carers and 
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Carers and physicians: Kappa < 0.5 for all 
domains except mobility. 
physicians, except for mobility 
domain.Uncertainty about the severity of 
dementia at which patients are able to 
provide valid ratings. 
Silberfeld , 2002(11) Content validity EQ-5D has less HRQoL attributes than QWB. 
Patients and carers identified more dementia-
related HR-QoL attributes associated with 
physical function (fatigue, sleep disturbances, 
loss of appetite, incontinence), emotional 
well-being (religion, personal losses), cognition 
(memory, reading, communication) and 
functional well-being (driving, exercising, 
travelling). 
 
Karlawish, 2008
b
(8) Known-group validity No association between patient proxy EQ-5D 
scores and MMSE (P = 0.13). 
 
  No association between patient proxy EQ-5D 
scores and QoL-AD, IADL, and BADL (P < 
0.0001). 
 
BADLS, Bristol Activities of Daily Living Scale; BADL, basic activities of daily living; CDR, Clinical Dementia Rating; HUI, Health Utility Index; IADL, Instrumental Activities of 
Daily Living; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; QoL-AD, Quality of Life WAlzheimer's Disease; QWB, Quality of Well being. 
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Table A5: Responsiveness assessment in studies in the systematic review for dementia (WP 1.1) 
Author, Year 
 
Method of measuring 
responsiveness (e.g. effect 
sizes, statistical 
significance) 
Responsiveness results 
 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ 
Karlawish, 2008
a
 
(3) 
Tendency towards a single 
level response 
More than one-third of patients rated themselves at the highest level 
of HRQoL for several or all five EQ-5D dimensions 
Ceiling effect for patient self-ratings. 
Naglie, 2006(7) 
 
Tendency towards a single 
level response 
More than one-third of patients rated themselves at the highest level 
of HRQoL for several or all five EQ-5D dimensions 
Ceiling effect for patient self-ratings with  EQ-
5D, but not with QWB and HUI.  
Coucill, 2001(4) 
 
Tendency towards a single 
level response 
More than one-third of patients rated themselves at the highest level 
of HRQoL for several or all five EQ-5D dimensions 
Ceiling effect' for patient ratings. 
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Table A6: Fields collected in the hospital organisational checklist of the NAD 
 Hospital code 
Contact details of data collector (Name, Job title; Email address; Telephone) 
GOVERNANCE 
 A care pathway for patients with dementia is in place? 
The care pathway is adaptable for use within or fitted to the following existing care pathways: acute, 
palliative, end of life? 
A senior clinician is responsible for implementation and/or review of the care pathway? 
Senior clinician who leads the work of the hospital or Trust on this 
There is a named officer with designated responsibility for the protection of vulnerable adults? 
The Executive Board regularly reviews information collected on: 
 Re-admissions, in which patients with dementia can be identified in the total number of patients 
readmitted? 
 Delayed discharge/transfers, in which patients with dementia can be identified in the total number 
of patients with delayed discharge/transfers? 
The Executive Board regularly reviews the number of in-hospital falls and the breakdown of the 
immediate causes, in which patients with dementia can be identified? 
The Executive Board regularly receives feedback from the following: 
Clinical Leads for older people and people with dementia including Modern  
 Matrons/Nurse consultant? 
 Complaints  W analysed by age? 
 Patient Advice and Liaison Services   W in relation to services for older people and people with 
dementia? 
 Patients forums or Local Involvement Networks  W in relation to services for older people and people 
with dementia? 
There is a process in place to regularly review hospital discharge policy and procedures, as they relate to 
people with dementia? 
Nursing staff have access to a recognised process to record and report risks to patient care if they believe 
ward staffing is inadequate? 
There are champions for dementia at Directorate level, Ward level? 
Comments on Governance 
SECTION 2: DELIVERY OF CARE 
 Multidisciplinary assessment includes: 
 Problem list? 
 Comorbid conditions? 
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 Current medication including dosage and frequencies? 
 Assessment of functioning using a standardised instrument  W i.e. basic activities of daily living, 
instrumental activities of daily living, mobility? 
 Assessment of mental state using a standardised instrument  W i.e. mental status (cognitive) testing? 
 Nutritional status? 
ƐƉĂƌƚŽĨŝŶŝƚŝĂůĂƐƐĞƐƐŵĞŶƚ ?ƚŚĞƉĂƚŝĞŶƚ ?ƐBMI (Body Mass Index) or weight is recorded, wherever 
possible? 
Social and environmental assessment includes support provided to the ƉĞƌƐŽŶ ‘ŝŶĨŽƌŵĂůůǇ ? ? 
Social and environmental assessment includes care provision assessment? 
Social and environmental assessment includes financial support assessment? 
Social and environmental assessment includes home safety assessment? 
tĂƌĚƐ ?ĂĚŚĞƌĞŶĐĞƚŽƉƌŽƚĞĐƚĞĚŵĞĂůtimes is reviewed and monitored? 
Comments on Delivery of Care 
MENTAL HEALTH NEEDS 
 There are policies or guidelines in place to ensure that patients with dementia or cognitive impairment 
are assessed for the presence of delirium at presentation? 
There are policies or guidelines in place to ensure that patients with dementia or cognitive impairment 
with behaviour changes suggesting the presence of delirium, are clinically assessed by a healthcare 
professional who is trained and competent in the diagnosis of delirium? 
There are systems in place to ensure that where dementia is suspected but not yet diagnosed, this 
triggers a referral for assessment and differential diagnosis either in the hospital or in the community 
(memory services)? 
There is a policy or guideline stating that an assessment of mental state is carried out on all patients over 
the age of 65 admitted to hospital? 
There is a protocol in place governing the use of interventions for patients displaying violent or 
challenging behaviour, aggression and extreme agitation, which is suitable for use in patients who 
present behavioural and psychological symptoms of dementia? 
The protocol specifies that restraint and sedation is used only as a final option? 
The protocol specifies consideration of physical causes which may cause challenging behaviour in people 
with dementia? 
The protocol considers environmental factors such as noise, lack of activity, disorientation? 
The protocol specifies the possibility of using techniques of reassurance de-escalation, distraction? 
The protocol specifies the risks that must be assessed and taken into account before any use of restraint 
or sedation in people with dementia and the frail elderly? 
The protocol specifies any prescription and administration of antipsychotic drugs is in line with NICE 
guidance? 
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There is a section or prompt in the general hospital discharge summary for mental health diagnosis and 
management? 
Comments on Mental Health needs 
DISCHARGE AND TRANSFER POLICIES  
 The discharge policy states that discharge should be an actively managed process which begins within 24 
hours of admission? 
The discharge policy specifies that: 
 Discharge should take place during the day? 
 Relatives and carers should be informed and updated about the prospective discharge date? 
Information about discharge and support (written in plain English or Welsh, and available in other 
appropriate languages) is made available to patients and their relatives? 
The discharge policy specifies that this information is made available to patients and their relatives on 
admission? 
The written information about discharge provided to patients and relatives contains information about 
organisations representing people with dementia and carers? 
The transfer policy specifies that: 
 The transfer policy can be part of the discharge policy? 
 People with dementia should be moved only for reasons pertaining to their care and treatment? 
 The move should take place during the day? 
Relatives and carers should be kept informed of any moves within the hospital 
Comments on Discharge and transfer policies 
INFORMATION 
 There is a formal system (pro-forma or template) in place for gathering information pertinent to caring 
for a person with dementia? 
Information collected by the pro-forma includes personal details, preferences and routines? 
Information collected by the pro-forma includes reminders or support with personal care? 
Information collected by the pro-forma includes recurring factors that may cause of exacerbate distress? 
Information collected by the pro-forma includes support or actions that can calm the person if they are 
agitated? 
Information collected by the pro-forma includes details of life details which aid communication? 
The form prompts staff to approach carers or relatives to collate necessary information? 
Comments on Information 
RECOGNITION OF DEMENTIA 
 There is a system in place across the hospital that ensures that all staff in the ward or care area are aware 
of the person's dementia or condition and how it affects them? Please say what this system is? 
There is a system in place across the hospital that ensures that staff from other areas are aware of the 
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ƉĞƌƐŽŶ ?ƐĚĞŵĞŶƚŝĂŽƌ condition whenever the person accesses other treatment areas? Please say what 
this system is? 
The patient's notes are organised in such a way that it is easy to: 
 Identify any communication or memory problems? 
 See the care plan? 
There is a system in place to ensure that carers are ĂĚǀŝƐĞĚĂďŽƵƚŽďƚĂŝŶŝŶŐĐĂƌĞƌ ?ƐĂƐƐĞƐƐŵĞŶƚĂŶĚ
support? 
There are clear guidelines regarding involvement of carers and information sharing. This includes: 
Making sure the carer knows what information will be shared with them? 
Asking the carer about the extent they prefer to be involved with the care and support of the person with 
dementia whilst in the hospital? 
Asking the carer about their wishes and ability to provide care and support of the person with dementia 
post discharge? 
Comments on Recognition of Dementia 
TRAINING, LEARNING AND DEVELOPMENT 
 There is a training and knowledge framework or strategy that identifies necessary skill development in 
working with and caring for people with dementia? 
Staff induction programmes include dementia awareness? 
The following questions are about training that is provided to acute healthcare staff who are involved in 
the care of people with dementia (or suspected dementia): 
 Dementia awareness training? 
 Protection of vulnerable adults? 
 How to support people with hearing/visual impairments? 
 Mental Capacity Act? 
 Communication skills specific for people with dementia? 
 Approaches to behaviour that challenges including management of aggression and extreme 
agitation? 
 Assessing risk whenever the use of restraint or sedation is considered? 
 Involvement of people with dementia and carers and use of their experiences is included in the 
training for ward staff? 
 Liaison teams from local mental health and learning disability services offer regular training for 
healthcare professionals in the hospital who provide care for people with dementia? 
Comments on Training, learning and development 
SPECIFIC RESOURCES SUPPORTING PEOPLE WITH DEMENTIA 
 The hospital has access to intermediate care services, which will admit people with dementia? 
Access to intermediate care services allows people with dementia to be admitted to intermediate care 
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directly and avoid unnecessary hospital admission? 
There is a named dignity lead to provide guidance, advice and consultation to staff? 
There is a named person who takes overall responsibility for complex needs discharge and this includes 
people with dementia? This person has training in ongoing needs of people with dementia? This person 
has experience of working with people with dementia and their carers? 
There is a social worker or other designated person responsible for working  
with people with dementia and their carers, and providing advice and support, or directing to appropriate 
organisations or agencies? 
There is access to specialist assessment and advice on helping patients with dementia in their swallowing 
and eating? 
Specialist assessment and advice can be obtained from: 
 Speech and Language Therapist? 
 Dietician? 
 Other? 
There is access to an interpreting service which meets the needs of people with dementia in the hospital? 
There is access to advocacy services with experience and training in working with people with dementia? 
Comments on Specific resources supporting people with dementia 
LIAISON PSYCHIATRY 
 The hospital provides access to a liaison psychiatry service which can provide assessment and treatment 
to adults throughout the hospital? 
The liaison service provides emergency/urgent assessment? 
There is a named Consultant Psychiatrist? 
The Consultant Psychiatrist has dedicated time in his/her job plan for the provision of this service? 
The Consultant Psychiatrist specialises in the care and treatment of older people? 
Liaison psychiatry is provided by a specialist mental health team? 
The liaison service in your hospital regularly provides? 
Times when liaison psychiatry is available 
Where the liaison psychiatry team is based 
Do all healthcare professionals who are part of the liaison psychiatry service have dedicated time? 
If there is no specialist mental health team, who does provide liaison psychiatry/mental health input? 
Extracted from the PDF file available on: 
 http://www.rcpsych.ac.uk/pdf/CCQI%20NAD%20organisational%20checklist%20round%202.pdf 
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Table A7: Fields collected in the Casenote audit of the NAD 
 Hospital code 
Has the patient been in hospital for 5 days or longer?  
Case note number 
Has this case note been selected as a data reliability check? 
Contact details of data collector (Name, Job title; Email address; Telephone) 
INFORMATION ABOUT THE PATIENT 
 Age, Gender, Ethnicity, First language, Ward Speciality (where patient spent the longest period during the 
admission), Death at the hospital, Self-discharge, End of Life Care or End of Life Pathway, Admission date, 
Discharge or Death date, Place of Living or Care before Admission,  Place of Living or Care after Discharge, 
Comments about Patient 
ASSESSMENT
 
 ,ĂƐƚŚĞƉĂƚŝĞŶƚ ?ƐŵĞŶƚĂůŚĞĂůƚŚŚŝƐƚŽƌǇďĞĞn recorded  W dementia or other conditions or symptoms? 
COMPREHENSIVE ASSESSMENT OF THE OLDER PERSON

 a
  
 MULTIDISCIPLINARY ASSESSMENT:  
The multidisciplinary assessment includes problem list? 
The multidisciplinary assessment includes comorbid conditions? 
The assessment includes a record of current medication, including dosage and frequency? 
The multidisciplinary assessment includes comorbid conditions? 
An assessment of nutritional status was performed by a healthcare professional? 
The assessment of nutritional status includes recording of BMI (Body Mass Index)/weight? 
Has a formal pressure sore risk assessment been carried out and score recorded? 
As part of the multidisciplinary assessment has the patient been asked about any continence needs? 
As part of the multidisciplinary assessment has the patient been asked about the presence of any pain? 
Has an assessment of functioning, using a standardised assessment, been carried out? 
 
MENTAL ASSESSMENT: 
Has a standardised mental status test been carried out? (e.g. MMSE) 
Has an assessment been carried out for recent changes or fluctuation in behaviour that may indicate the 
presence of delirium? 
Has the patient been clinically assessed for delirium by a healthcare professional? 
 
SOCIAL AND ENVIRONMENTAL ASSESSMENT: 
Has a need for care assessment by a social worker been identified? 
Has a care assessment by a social worker been requested? 
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Has a care assessment by a social worker been carried out? 
Did the assessment include an assessmĞŶƚŽĨƐƵƉƉŽƌƚƉƌŽǀŝĚĞĚƚŽƚŚĞƉĞƌƐŽŶ ‘ŝŶĨŽƌŵĂůůǇ ? ? 
Did the assessment include a formal care provision assessment? 
Did the assessment include a financial support? 
Did the assessment include a home safety? 
 
INFORMATION ABOUT THE PERSON WITH DEMENTIA: 
Does the care assessment contain a section dedicated to collecting information from the carer, next of 
kin or a person who knows the patient well? 
Has information been collected about the patient regarding reminders or support with personal care? 
Has information been collected about the patient regarding recurring factors that may cause of 
exacerbate distress? 
Has information been collected about the patient regarding support or actions that can calm the person if 
they are agitated? 
Has information been collected about the patient regarding details of life details which aid 
communication? 
Has information about support on discharge been given to the patient and/or the carer?  
 
DISTRESS, AGITATION AND BEHAVIOUR THAT CHALLENGES: 
Has this patient had antipsychotic drugs at any point during admission (whether or not prescribed in the 
hospital)? 
On admission, was the patient taking antipsychotics due to an existing regular prescription? 
Was a PRN prescription for antipsychotics in place for this admission? 
Was an antipsychotic administered via PRN? 
Was a new or additional prescription made for an antipsychotic? 
What was the main or primary reason recorded for prescription of antipsychotics? 
What are the other reasons recorded for prescription of antipsychotics?  
DISCHARGE 
 ASSESSMENT BEFORE DISCHARGE 
 At the point of discharge the patient's level of cognitive impairment, using a standardised assessment, 
was summarised and recorded? 
At the point of discharge the cause of cognitive impairment was summarised and recorded? 
Have there been any symptoms of delirium? 
Have the symptoms of delirium been summarised for discharge? 
Have there been any persistent behavioural and psychiatric symptoms of dementia (wandering, 
aggression, shouting) during this admission? 
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Have the symptoms of behavioural and psychiatric symptoms of dementia been summarised for 
discharge?  
Is there any record in the discharge summary/notes that there is a prescription of antipsychotics that is 
being continued post discharge? 
  
DISCHARGE COORDINATION AND MULTIDISCIPLINARY TEAM INPUT: 
Did a named person coordinate the discharge plan? 
Is there evidence in the notes that the discharge coordinator/person planning discharge has discussed 
appropriate place of discharge and support needs with the person with dementia? 
Is there evidence in the notes that the discharge coordinator/person planning discharge has discussed 
appropriate place of discharge and support needs with the person's carer/relative? 
Is there evidence in the notes that the discharge coordinator/person planning discharge has discussed 
appropriate place of discharge and support needs with the consultant respŽŶƐŝďůĞĨŽƌƚŚĞƉĂƚŝĞŶƚ ?ƐĐĂƌĞ ?
Is there evidence in the notes that the discharge coordinator/person planning discharge has discussed 
appropriate place of discharge and support needs with other members of the multidisciplinary team? 
Has a single plan for discharge with clear updated information been produced? 
Are any support needs that have been identified documented in the discharge plan or summary? 
Has the patient and/or carer received a copy of the plan or summary? 
 
DISCHARGE PLANNING: 
Was discharge planning initiated within 24 hours of admission? 
Reason why discharge planning could not be initiated within 24 hours 
 
SUPPORT FOR CARERS AND FAMILY: 
Carers or family have received notice of discharge and this is documented? 
An asseƐƐŵĞŶƚŽĨƚŚĞĐĂƌĞƌ ?ƐĐƵƌƌĞŶƚŶĞĞĚƐŚĂƐƚaken place in advance of discharge? 
Comments about Discharge 
LIAISON PSYCHIATRY 
 Has any referral been made to psychiatric consultation/liaison? 
Has any need for referral to liaison psychiatry been noted on admission or during further assessment? 
Has a follow up referral to community based mental health services been made on discharge? 
Is it stated whether the referral was emergency, urgent or routine? 
Time between referral and assessment 
What was the main reason given for referral? 
Comments about Liaison Psychiatry 
RECORD KEEPING 
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 Is information about the person's dementia quickly found in a specified place in the file?  
Is information about related care and support needs quickly found in a specified place in the file?  
In your opinion, how would you rate the organisation of this case note? 
Comments about Record Keeping 
a 
conducted on admission or after patient is well enough  
Extracted from the PDF file available on: 
http://www.rcpsych.ac.uk/pdf/CCQI%20NAD%20casenote%20audit%20round%202.pdf 
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